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Abstract. Gait disturbances are some of the earliest changes in dementia and their monitoring presents an opportunity for
early diagnosis. The exact relationship between gait and well-established biomarkers of Alzheimer’s disease (AD) remains
to be clarified. In this study we compared gait-related measures with cerebrospinal fluid (CSF) markers of AD pathology. We
recruited seventeen participants with mild AD in a multi-site study and performed gait assessment as well as lumbar punctures
to obtain CSF. CSF A42/A40 and A42/A38 correlated positively with measures of variability (step time and step length)
in the clinic-based assessments. This was driven by a negative relationship between gait variability and A40 and A38 but
not A42.The amyloid ratios and gait variability measures were also associated with more severe functional impairment.
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We interpret these data as an indication that increasing amyloid production (i.e., increasing A40 and A38) is associated with
diminishing cognitive-motor control of gait. These preliminary results suggest that the two amyloid ratios may be a marker
of the earliest disturbances in the interplay between cognitive and motor control which characterize dementia.
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INTRODUCTION
The re-conceptualization of Alzheimer’s disease
(AD) as a continuum of disorders spanning from
intact cognition in the context of abnormal biomark-
ers of AD pathology to dementia has led to calls for
a shift toward earlier diagnosis of dementia, before
significant cognitive and functional impairment man-
ifest [1]. Achieving this would allow researchers
to develop a better understanding of the preclinical
phase of disease. In this respect, features identifi-
able in clinical and home settings that occur prior
to marked cognitive impairment are of particular
interest and gait disturbance is potentially valuable.
Walking is a complex cognitive and motor process
that is sensitive to the loss of higher order cognitive
control, with studies showing that gait impairment
is associated with poor attention and memory [2–4].
The relevance to early diagnosis is demonstrated by
studies showing gait disturbances in dementia start to
develop up to 12 years before first symptoms [5]. In
addition, poorer motor function and slower walking
speed act as predictors for cognitively healthy indi-
viduals converting into mild cognitive impairment
(MCI) [5] as well as MCI progressing to demen-
tia [6–8], leading to the proposition that change to
the variability of gait parameters is a hallmark of
the earliest stages of the disease [9, 10]. The link of
the observed gait disturbance to the underlying AD
pathology, however, remains largely unclarified.
Accumulation of amyloid- (A) plaques is one
of the pathophysiological hallmarks of AD. Quantifi-
cation of A in cerebrospinal fluid (CSF) is the best
validated fluid biomarker for obtaining in vivo infor-
mation on amyloid accumulation [11] with decreased
levels of A42 consistently found in AD [12]. Several
shorter forms of A are also present (A40 and A38)
and evidence points to A42/A40 and A42/A38
ratios being more specific to A plaque pathology
than A42 alone [13]. Low levels of A42 in the CSF
predict gait decline in other neurodegenerative disor-
ders such as Parkinson’s disease although it is unclear
whether such a link also exists in dementia [14].
In this study, we sought to clarify the relationship
between gait abnormalities in AD and CSF markers
of AD pathology in a group of people with clinical
diagnosis of AD. We hypothesized that more severe
pathology (lower CSF A) will be associated with
indices of worsening gait and impaired activities of
daily living.
METHODS
Participants
Patients with mild AD were recruited from six
centers of excellence in the UK as part of the pilot
Deep and Frequent Phenotyping (DFP) study [15,
16]. The main inclusion criteria for the DFP study
were diagnosis of AD according to NIAA criteria
[17]; MMSE score above 20; age between 55 and 80;
Rosen modified Hachinski ischemic score ≤4; ability
to walk independently for at least 15 m (see previ-
ous publication [15] for a description of the study
design). Participants were assessed over a 6-month
period during which they completed a battery of tests,
including gait (clinic-based assessments at Day 169)
assessments and cerebrospinal fluid (baseline and
Day 182) analyses reported here. Dementia severity
was assessed using Clinical Dementia Rating (CDR)
[18] and the presence of depressive symptoms using
the Geriatric Depression Scale (GDS) [19]. Level of
function was evaluated using the Bristol Activities of
Daily Living Scale (BADLS) [20].
Gait procedures
Clinic-based assessments employed single- and
dual-task testing conditions. For both, participants
were required to walk in a straight line for 6 m
(repeated 6 times) or 10 m (repeated 4 times), depend-
ing upon availability of clinic space. Under the
single-task condition participants were requested to
walk in a straight line only. When performing the
dual task, participants walked while reciting strings
of numbers, the length of which was determined
by their seated digit span (forward) performance
[21]. Gait outcomes were derived from a theoreti-
cal model based on a principal component analysis
[22] and included a range of characteristics sensitive
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to cognition [23]. For the clinic-based assessments,
gait characteristics were extracted based on temporal
algorithms identifying initial and final contact events
within the gait cycle [21].
CSF analysis
CSF was collected at the baseline visit and
6-month follow-up. A42, A40, and A38 con-
centrations were measured using the MSD A
Triplex assay (Meso Scale Discovery, Rockville,
MD). Well-established standard operating protocols
for sample collection and management were used
[12] and assays performed according to manufac-
turer’s instructions, as previously described in detail
[24]. All measurements were performed by board-
certified laboratory technicians who were blinded to
clinical data. The measurements were performed on
one occasion using one batch of reagents. Intra-assay
coefficients of variation were below 10% and all sam-
ples measured in the quantitative range of the assays.
Statistical analysis
SPSS (Version 25) was used to analyze the data.
The relationship between amyloid CSF measures
(A42/A40, A42/A38 ratios as well as A42,
A40, and A38) and gait measures were com-
pared using two-way Spearman’s correlations. For
the clinic-based assessment. we examined step veloc-
ity, step length and its variability, and step time and
its variability for the single- and dual-task conditions
[21]. Significant correlations between gait and CSF
measures were followed with Spearman’s correla-
tions with the BALDS score, a measure of function in
dementia. A threshold of p < 0.05 was used to guide
statistical interpretation.
Ethics
The study was approved by a National Research
Ethics Committee London on 19 September 2014
(reference 14/LO/1467). All participants had mental
capacity for informed consent.
RESULTS
Demographics and clinical measures
17 participants underwent lumbar puncture on at
least one occasion (14 at baseline and 6 months,
1 completed the baseline only and 2 the follow-up
only). To obtain 17 full CSF datasets, we averaged
Table 1
Summary of demographic and clinical
variables with mean values and standard
deviations (in brackets); amyloid isomer
concentrations expressed in pg/ml
Mean (SD)
Age 67 (7.5)
MMSE 25 (2.4)
CDR 0.7 (0.2)
BADLS 4 (3.4)
GDS 2.2 (1.4)
A38 2234.2 (731.7)
A40 5576.8 (1405.4)
A42 288.4 (76.6)
A42/A40 0.05 (0.01)
A42/A38 0.14 (0.04)
the biomarker values for those with two measure-
ments and used the single measurement for the
other participants. Mean and standard deviation
values for CSF measures were as follows: A38
2234.2 ± 731.7 pg/ml; A40 5576.8 ± 1405.4 pg/ml;
A42 288.4 ± 76.6 pg/ml; A42/A40 0.05 ± 0.01
and A42/A38 0.14 ± 0.04. Of the 17 participants
who had CSF sampling, 16 had the clinic-based and
free-living gait testing, respectively. Mean age of the
sample was 67 years (SD 7.5) and 8 of 17 were
female. AD severity was mild (mean MMSE was 25,
SD 2.4; mean CDR was 0.7, SD 0.2) with minimal
functional impairment affecting independence (mean
BADLS of 4, SD 3.4) and were not depressed (mean
GDS score of 2.2, SD 1.4). See Table 1 for a summary
of the demographic and clinical measures.
Gait and Aβ relationships
For both single- and dual-task conditions of the
clinic-based assessment there were no significant cor-
relations between the amyloid ratios or individual A
peptides and step velocity, length, and time. For the
single condition task, however, the variability in step
length and the variability in step time were correlated
positively with A42/A40 and A42/A38 ratios.
The variability in step length and the variability in
step time were negatively correlated with A38 and
A40 but not A42 levels. Similarly, in the dual-task
condition, the variability in step length and the vari-
ability in step time were correlated positively with
A42/A40 and A42/A38. The variability in step
length was negatively correlated with A40 and A38
but not A42 levels. However, in the dual-task con-
dition, there was no significant relationship between
the variability in step time and any of the individual
amyloid peptide measures (Table 2, Fig. 1A-B).
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Table 2
Summary of study comparisons (Spearman’s Rho coefficient and p value in brackets, significant (p < 0.05)
results in bold)
Gait Task A42/A40 A42/A38 A42 A40 A38
Single Task Condition
Step Velocity –0.07 (0.80) –0.14 (0.62) 0.25 (0.36) 0.11 (0.69) 0.23 (0.40)
Step Length –0.01 (0.97) –0.09 (0.74) 0.19 (0.49) 0.04 (0.88) 0.20 (0.45)
Step Length Variability 0.60 (0.02) 0.60 (0.01) 0.06 (0.82) –0.54 (0.03) –0.55 (0.03)
Step Time 0.14 (0.60) 0.16 (0.56) –0.23 (0.38) –0.18 (0.5) –0.20 (0.45)
Step Time Variability 0.59 (0.02) 0.62 (0.01) –0.04 (0.88) –0.56 (0.02) –0.64 (<0.01)
Dual Task Condition
Step Velocity –0.02 (0.95) –0.04 (0.88) 0.19 (0.49) –0.02 (0.93) 0.09 (0.75)
Step Length 0.06 (0.84) –0.02 (0.95) 0.07 (0.80) –0.12 (0.66) 0.07 (0.81)
Step Length Variability 0.67 (<0.01) 0.66 (<0.01) 0.14 (0.59) –0.51 (0.04) –0.54 (0.03)
Step Time –0.08 (0.77) –0.12 (0.65) –0.15 (0.57) 0.14 (0.61) 0.15 (0.58)
Step Time Variability 0.62 (0.01) 0.56 (0.03) 0.14 (0.59) –0.4 (0.13) –0.4 (0.13)
Fig. 1. Relationships between CSF with gait (A, B) and daily function (C, D).
To assess the functional significance of the
observed relationships, we correlated BADLS score
with the clinic-based variability measures. BADLS
correlated positively with the variability in step length
(Spearman’s Rho = 0.7, p < 0.01 and 0.56, p = 0.02
for single and dual task conditions respectively) and
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the variability in step time (Spearman’s Rho = 0.6,
p < 0.01 and 0.48, p = 0.05 for single and dual task
conditions respectively). In addition, BADLS corre-
lated positively with A42/A40 ratio (Spearman’s
Rho = 0.53, p = 0.03) and A42/A38 ratio (Spear-
man’s Rho = 0.47, p < 0.05), but not with any of the
individual amyloid peptide measures (Fig. 1C-D).
DISCUSSION
In this pilot study, we found an association between
measures of gait variability and CSF amyloid markers
of AD pathology (A42/A40 and A42/A38 ratios)
in a group of mild AD patients. The association was
driven by negative correlations between the measures
of gait variability and the individual levels of A40
and A38 isoforms as there was no significant associ-
ation between measures of gait variability and A42
level. We also found that both the measures of gait
variability and amyloid ratios correlated with severity
of impairment in activities of daily living.
The finding of an association between measures
of A peptides and gait variability rather than the
average gait characteristics (step length, time, and
velocity) is potentially interesting. Changes to mea-
sures of gait variability are common features of
age-related cognitive impairment and neurodegen-
erative disorders. They are associated with poor
mobility as well as increased risk of falls, and are
a harbinger of future cognitive decline [25]. Mea-
sures of gait variability may also be associated with
dementia severity and may even help distinguish
between dementia subtypes [10]. However, the under-
lying mechanisms of increased gait variability are
poorly understood. One potential theory is that the
increased variability is an early compensatory mech-
anism, where the variability in clinical outcomes
increases to account for decreasing physiological
reserve. The proposed theory predicts that in later
stages these compensatory mechanisms fail leading
to declining variability [26]. The negative relation-
ships between CSF A40 and A 38 isoform levels
and measures of gait variability in our sample of indi-
viduals with mild AD are consistent with this theory.
However, it is unclear whether measures of gait vari-
ability will decline with increasing disease severity,
as predicted by MacDonald et al. [26], or increase
further with declining cognitive control of gait [9].
That the relationship between gait and A40 and A
38 peptides was significant only in the simpler condi-
tion (single-task) relative to the more complex one
(dual-task) may be due to a larger variation in
response to dual-task paradigms as previously
observed in older adults with and without Parkin-
son’s disease [27]. The findings from this small study
add to the growing postmortem and in vivo evi-
dence supporting a relationship between measures
of gait abnormalities and changes in A amyloid
metabolism. In a postmortem study, the rate of decline
in gait speed was associated with levels of AD
pathology especially in the putamen [28]. Using PET
amyloid imaging Del Campo and co-authors demon-
strated an association between regional amyloid
burden (putamen, occipital cortex, precuneus, and
anterior cingulate) and gait speed in non-demented
individuals [29]. Another study found that lower lev-
els of A42 were associated with gait decline in
patients with Parkinson’s disease [14].
In this study we found a statistically significant
negative correlation between measures of gait vari-
ability (step time and length variability) and CSF
A42/A40 and A42/A38 ratios, driven by changes
in A40 and A38 levels but not A42. The exact sig-
nificance of this is unclear, but CSF A40 and A38
isoform levels may represent measures of amyloid
production and/or turnover rather than a reflection
of sequestration into plaques as is thought to be the
case for A42. In our study, gait variability decreased
with increase in A40 and A38 thus suggesting a
relationship between true amyloid production and
deterioration of the neural control of gait. In addition
to differentiating between AD and other dementias
[13], it appears they carry additional information
about pathological burden in other conditions such
Parkinson’s disease where a relationship between
CSF alpha-synuclein and A40 and A38 rather than
A42 has been reported [30]. In another study in
Parkinson’s disease, ventricular enlargement as a
marker of neurodegeneration was associated with
CSF A38, A40, and A42 levels [31]. The lack of
relationship between A42 and gait measures is likely
explained by the A42 levels already being at a very
low level (mean 288 pg/ml), thus exercising a floor
effect.
The study is limited by its small sample size.
A larger version of this pilot study is underway to
validate these findings—the study will increase the
sample size and provide longitudinal gait and CSF
measurements. Another limitation is that to increase
the sample size, we averaged CSF measures for 14
participants (samples taken 6 months apart) while
for 3 participants we used their single measure taken
either at baseline or 6 months. We made this decision
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on the basis of a previous analysis that found no sig-
nificant change in CSF measures over this period in
the same population [15].
In conclusion, this is the first study to-date to
explore the link between gait and CSF amyloid
measures in early AD patients. We demonstrated
a relationship between measures of gait variabil-
ity and A42/A40 and A42/A38 levels, which
was mirrored in changes in activities of daily living
function. Thus, measures of gait variability may act
as an early marker of AD dementia. Further well-
powered longitudinal studies are required to confirm
this relationship and explore its change as the disease
progresses.
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